Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

The Pathologist / Issues / 2017 / Feb / Venerated Vesicles
Oncology Liquid biopsy Oncology

Venerated Vesicles

How can gold and extracellular vesicles help diagnose pancreatic cancer?

By William Aryitey 02/23/2017 1 min read

Share

Extracellular vesicles (EVs) could serve as strong cancer biomarkers since the membranous sacs carry signaling factors directly from their parent cell. The difficulty comes from current diagnostic techniques – a large sample of plasma is needed to carry out an EV assay, and this can often be time-consuming, expensive, and ultimately low-throughput. But a solution to that challenge may exist… researchers from Arizona, Texas, Maryland, and Beijing, have collaborated to discover a method of detecting EVs with just 1 µl of plasma from pancreatic cancer patients (1).

Why focus on pancreatic cancer? The aggressive disease undergoes early metastasis and has a high resistance to treatment – which is why only 7.7 percent of patients survive for more than five years after diagnosis (2). This is compounded by the fact that there is currently no effective, noninvasive biomarker for pancreatic cancer.

The investigational assay requires just a single droplet of unpurified plasma, and contains gold nanoparticle spheres and rods, that adhere to cancer-derived EVs from the pancreas. The EVs with attached nanospheres and nanorods appear bright yellow when viewed under a darkfield microscope. In addition to operating as a diagnostic, the researchers suggest that their assay could also be used to track pancreatic cancer progression and monitor therapeutic response, which could be useful since the membrane-bound EVs are much less susceptible to the degradation that conventional protein biomarkers often face. Although the investigators believe they’re a few years away from a regulatory submission, this proof-of-concept mouse model study gives hope of a future where the noninvasive diagnosis of pancreatic cancer and monitoring of therapy effectiveness might just be possible.

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. K Liang et al., “Nanoplasmonic quantification of tumour-derived extracellular vesicles in plasma microsamples for diagnosis and treatment monitoring”, Nature Biomed Eng, 1, (2017). National Cancer Institute, “Cancer stat facts: pancreas cancer”, (2017). Available at: http://bit.ly/2iFiljK. Accessed February 14, 2017.

About the Author(s)

William Aryitey

My fascination with science, gaming, and writing led to my studying biology at university, while simultaneously working as an online games journalist. After university, I travelled across Europe, working on a novel and developing a game, before finding my way to Texere. As Associate Editor, I’m evolving my loves of science and writing, while continuing to pursue my passion for gaming and creative writing in a personal capacity.

More Articles by William Aryitey

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

A Light in the Darkness
Liquid biopsy
A Light in the Darkness

March 4, 2022

2 min read

Spectroscopic liquid biopsy testing – a new route to brain cancer diagnostics

Biomarkers: The Bigger Picture
Liquid biopsy
Biomarkers: The Bigger Picture

April 27, 2022

1 min read

To unlock patient care, pathologists must focus on molecular pathology and ensure efficiency and effectiveness to improve testing. With this testing, patients can benefit from the best treatment to combat their disease.

Benchmarking… Liquid Biopsy
Liquid biopsy
Benchmarking… Liquid Biopsy

May 13, 2022

1 min read

A look at the last five years of publishing on liquid biopsy

Does Your Blood Know You Have Cancer?
Liquid biopsy
Does Your Blood Know You Have Cancer?

July 25, 2022

2 min read

Detection and monitoring are crucial for melanoma outcomes – could a blood test revolutionize both?

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.